Skip to main content

Table 1 Clinical Characteristics of Patients Who Received NK Cell Therapy

From: A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia

UPN Characteristics at Diagnosis HLA Status Donor KIR– Recipient HLA Mismatch Peak NK Cell Chimerism Adoptive NK Cell Transfer Days from NK cell transplant to relapse
Age at diagnosis (Years) Sex Karyotype Bw C % Day NK Cells− (106/kg)  
1 1.1 M t(11;19) 6/6 C1/C1 CD158a, CD158e1 0 7 16.5 –
2 1.6 F + 4,t(6;11),+der(6)t(6;11),+ 8,+ 13,+ 19 4/6 C2/C2 CD158b 1 14 11.5 629
3 2.1 M t(9;11),+X,+ 7,+ 8 4/6 C2/C2 CD158b 2 6 12.4 –
4 10.2 F 46,XX 4/6 C2/C2 CD158b 4 12 8.2 527
5 1.2 F t(1;22),+ 2,+ 8,+ 21,+der(22)t(1;22) 4/6 C1/C1 CD158a 23 7 46.9 617
6 15.4 F 46,XX 6/6 C1/C2 CD158e1 8 13 3.6 –
7 1.2 F t(11;19),t(12;19) 4/6 C2/C2 CD158b 2 8 36.9 –
8 0.1 F N/A 6/6 C1/C2 CD158e1 43 14 44.3 –
9 0.5 F der(10) 4/6 C1/C1 CD158a 15 7 26.8 –
10 4.5 M 46,XY 6/6 C1/C1 CD158a, CD158e1 6 7 14.8 300†
11 2.1 M t(1;11),+ 9 6/6 C1/C1 CD158a, CD158e1 2 7 25.7 –
12 13.2 F + 8,t(11;19),+ 17,+ 19 6/6 C1/C1 CD158a, CD158e1 15 7 6.7 228
13 15.3 F + 21 4/6 C1/C1 CD158a 14 12 5.2 –
14 12.4 M t(1;2),del(9),-12,t(17;20),der(18) 4/6 C1/C1 CD158a 3 7 8.8 186†
15 1.6 M + 8,t(9;11;14) 4/6 C2/C2 CD158b 0 7 12.5 –
16 14.3 F ins(10;11),ins(17;11) 4/6 C1/C1 CD158a 22 7 5.7 231†
17 0.7 M t(5;6) 4/6 C2/C2 CD158b 32 21 42.4 –
18 3.0 M 46,XY 4/6 C1/C1 CD158a 0 7 62.6 –
19 4.0 M 46,XY 4/6 C1/C1 CD158a 4 7 12.4 –
20 12.2 M +X,+ 9,+ 11,+ 14,+ 20 6/6 C1/C2 CD158e1 1 7 9.0 367
21 9.2 M 46,XY 6/6 C1/C1 CD158a, CD158e1 10 7 19.3 –
  1. Abbreviations: CNS central nervous system, HLA human leukocyte antigen, KIR killer immunoglobulin-like receptor, N/A not available, NK natural killer, UPN unique patient number. † Deceased
Back to article page